November 8, 2024 8:02am

I CONTINUE to write about the earnings’ season of concern

Pre-Open Indications; 4 Sell into Strength and 4 BUYs

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

Never leave an investor uninform

RegMed Investors (RMi) Closing Bell: cell and gene therapy sector slippage … https://www.regmedinvestors.com/articles/13689

RegMed Investors (RMi) Research Note: Q3/24 earnings reporting dates, net losses, cash positions, revenue and runway outcomes … https://www.regmedinvestors.com/articles/13441

RegMed Investors (RMi) - Q3/24 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628

 

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

 

Friday: The pre-open Dow futures are UP +0.04% (+18 points), the S&P futures are DOWN -0.05% or (-2 points) and the Nasdaq futures are DOWN -0.19% or (- 41 points)

  • U.S. stock futures fell slightly on Friday, 11/8
  • European markets were lower,
  • Asia-Pacific markets were mixed.

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Thursday: The Dow closed DOWN -0.59 points or -0.00%, the S&P closed UP +44.06 points or +0.74% while the Nasdaq closed UP +285.99 points or +1.51%

  • Thursday’s advance/decline line ended with a negative close at the close of 11 incliner, 20 decliners and 4 flats

Economic Data Docket: University of Michigan consumer sentiment, November preliminary (71 expected, 70.5 prior)

 

Q4/24: November 2 negative and 3 positive closes

  • October: 8 positive and 15 negative closes

Q3/24:

  • September – 10 positive and 10 negative close
  • August – I neutral, 10 positive and 11 negative closes
  • July: 1 market holiday. 1 day off, 6 negative, 1 neutral and 12 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context 

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Let them roll after the sector dived post a spike with the market’s shallowing ascension; although ...

SELL into Strength:

Blueprint Medicine (BPMC) closed up with a positive +$1.61 or +1.59% aftermarket

CRISPR therapeutics (CRSP) closed up +$1.16 with a positive +$0.12 or +0.23% aftermarket

Sage Therapeutics (SAGE) closed up +$0.37 with a positive +$0.12 or +1.90% aftermarket

Vericel (VCEL) closed up =$1.99 with ma positive +$0.95 or +1.90% aftermarket

 BUY

Alnylam Pharmaceuticals (ALNY) closed down -$0.79 with a positive +$0.40 or +0.15% aftermarket

AxoGen (AXGN) closed down -$2.06 with a positive +$0.01 or +0.08% aftermarket

Ionis Pharmaceuticals (IONS) closed down -$0.58 with a positive +$0.41 or +1.07% aftermarket

Moderna (MRNA) closed down -$1.53 with a negative -$0.22 or -0.44% aftermarket

 

 

The BOTTOM LINE: I see a “shaky” market and an even “wobblier” sector as the week-ends.

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

U.S. equity futures edged lower in early Friday trading, but are still on pace for their best week of the year, as investors salute former President Donald Trump election’s win and a Fed rate cut that “could/should” be the last of the year.

 

Thursday performance:

  • The top three (3) performing in the session:   Vericel (VCEL), Regenxbio (RGNX) and Blueprint Medicine (BPMC)
  • The worst three (3) in the session:  AxoGen (AXGN), Moderna (MRNA) and Alnylam Pharmaceuticals (ALNY)

 

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.